ArticleCell reports. Medicine2026
Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antigenic heterogeneity and the tumor microenvironment remain major obstacles to effective chimeric antigen receptor T (CAR-T) therapy, but natural ligands engaging multiple antigens within tumors and their milieu offer a promising solution. Here, we present a multitarget switchable CAR-T (sCAR-T) strategy that integrates a universal receptor on T cells with an antibody-ligand motif, combining an anti-Her2 single-chain variable fragment (scFv) (4D5) and spliced VEGF-A (VEGF121) to target Her2, VEGFR1, and VEGFR2. Optimization of the switch and CAR hinge preserved the ligand's native dimeric conformation, enhancing antigen recognition and promoting immunological synapse formation. In syngeneic and xenograft models, sCAR-T achieves superior tumor eradication and vasculature disruption compared with conventional CAR-T, overcoming immune escape driven by antigenic heterogeneity. We further extend the sCAR-T design to target receptor tyrosine kinase-like orphan receptor 1 (ROR1), demonstrating that the antibody-ligand motif-based strategy provides a versatile framework for complex antigen targeting, with potential to improve efficacy and safety and enable broader application in immunotherapies targeting complex antigenic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.